Joseph Woodard
Patrimonio netto: 4 142 $ in data 31/08/2026
Patrimonio netto: 4 142 $ in data 31/08/2026
Joseph Paul Woodard formerly worked at Bellicum Pharmaceuticals, Inc., as Senior Vice President-Clinical & Medical Affairs in 2019, Imugene Ltd., as Chief Medical Officer from 2023 to 2025, and Immune-Onc Therapeutics, Inc., as Chief Medical Officer & Senior Vice President.
Dr. Woodard received his undergraduate degree from The University of North Carolina at Charlotte and doctorate degree from UNC School of Medicine.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
IMUGENE LTD 0,02% | 30/06/2025 | 85.007 ( 0,02% ) | 4 142 $ | 31/08/2026 |
| Società | Posizione | Fine |
|---|---|---|
| IMUGENE LIMITED | Direttore Tecnico/Scientifico/R&S | 30/05/2025 |
| BELLICUM PHARMACEUTICALS, INC. | Direttore Tecnico/Scientifico/R&S | 01/11/2019 |
Immune-Onc Therapeutics, Inc.
Immune-Onc Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company advancing novel therapies that target myeloid cells | Direttore Tecnico/Scientifico/R&S | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 5 |
|---|---|
Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops novel cellular immunotherapies for various forms of cancer | Health Technology |
Imugene Ltd.
Imugene Ltd. BiotechnologyHealth Technology Operates as a a clinical stage immuno-oncology company | Health Technology |
The University of North Carolina at Charlotte
The University of North Carolina at Charlotte Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
UNC School of Medicine
UNC School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immune-Onc Therapeutics, Inc.
Immune-Onc Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company advancing novel therapies that target myeloid cells | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale